Robert C Kain Net Worth

The estimated Net Worth of Robert C Kain is at least $16.2 million dollars as of 23 August 2005. Robert Kain owns over 10,000 units of Illumina Inc stock worth over $15,642,572 and over the last 21 years Robert sold ILMN stock worth over $569,340.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Robert Kain ILMN stock SEC Form 4 insiders trading

Robert has made over 5 trades of the Illumina Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Robert sold 10,000 units of ILMN stock worth $122,500 on 23 August 2005.

The largest trade Robert's ever made was selling 20,000 units of Illumina Inc stock on 12 August 2005 worth over $231,400. On average, Robert trades about 7,429 units every 25 days since 2004. As of 23 August 2005 Robert still owns at least 125,311 units of Illumina Inc stock.

You can see the complete history of Robert Kain stock trades at the bottom of the page.

What's Robert Kain's mailing address?

Robert's mailing address filed with the SEC is 9885 TOWNE CENTRE DR, , SAN DIEGO, CA, 92121.

Insiders trading at Illumina Inc

Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley et Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.

What does Illumina Inc do?

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Complete history of Robert Kain stock trades at Illumina Inc

Illumina Inc executives and stock owners

Illumina Inc executives and other stock owners filed with the SEC include:

• Mostafa Ronaghi,
  Senior Vice President of Entrepreneurial Development
• Mark Van Oene,
  Senior Vice President, Chief Commercial Officer
• Jay Flatley,
  Executive Chairman of the Board
• Joydeep Goswami,
  Senior Vice President - Corporate Development and Strategic Planning
• Charles Dadswell,
  Senior Vice President, General Counsel, Secretary
• Francis deSouza,
  President, Chief Executive Officer, Director
• Susan Siegel,
  Independent Director
• Dr. Alexander Aravanis M.D., Ph.D.,
  CTO & Head of Research and Product Devel.
• Aimee Hoyt,
  Senior Vice President and Chief People Officer
• Sam A. Samad,
  Chief Financial Officer
• Susan H. Tousi,
  Chief Commercial Officer
• Sam Samad,
  Chief Financial Officer, Senior Vice President
• Caroline Dorsa,
  Independent Director
• John Thompson,
  Lead Independent Director
• Robert Epstein,
  Independent Director
• Gary Guthart,
  Independent Director
• Frances Arnold,
  Independent Director
• Philip Schiller,
  Independent Director
• Jacquie Ross,
  Vice President, Investor Relations
• Scott Gottlieb,
  Independent Director
• Alex Aravanis,
  Chief Technology Officer
• Phillip Febbo,
  Senior Vice President, Chief Medical Officer
• Carissa Rollins,
  Chief Information Officer
• Sallilyn Schwartz,
  VP of Investor Relations
• Kevin Carl Pegels,
  Chief of Global Operations
• Francis A. deSouza,
  CEO & Director
• Charles E. Dadswell,
  Sr. VP, Gen. Counsel & Sec.
• Juliet Cunningham,
  VP of Investor Relations
• Steve Phillpott,
  Sr. VP & Chief Information Officer
• Jose A. Torres Jr.,
  Chief Accounting Officer & VP
• Robert P. Ragusa,
  Chief Operations Officer
• Stephanie Campos,
  Pres
• Kathryne Gambrell Reeves,
  SVP, Chief Marketing Officer
• Daniel Bradbury,
  Director
• A Blaine Bowman,
  Director
• Omead Ostadan,
  SVP Mktg, Prod & Strat Plan
• Karin Eastham,
  Director
• Patricia Leckman,
  SVP, Chief People Officer
• Malcolm Garret Hampton,
  SVP Clinical Genomics Group
• Karen K Mcginnis,
  VP, Chief Accounting Officer
• Jacob Thaysen,
  Chief Executive Officer
• Robert P Ragusa,
  SVP, Global Quality & Ops
• Susan H Tousi,
  SVP, Chief Commercial Officer
• David R Walt,
  Director
• William H Rastetter,
  Director
• Nicholas Naclerio,
  Sr VP, Corporate & Venture Dev
• Tristan Orpin,
  VP Worldwide Sales
• Richard Klausner,
  Sr VP, Chief Medical Officer
• Roy A Whitfield,
  Director
• Jeff Huber,
  Director
• Marc Stapley,
  Sr VP & CFO
• Gerald Moeller,
  Director
• Paul L Bianchi,
  Sr VP, Human Resources
• Michel Bouchard,
  Chief Accounting Officer
• Mark L Lewis,
  Sr VP & GM Molecular Biology
• Gregory Heath,
  Sr. VP and GM, Diagnostics
• Matthew L. Posard,
  Sr VP & GM, Consumer Genomics
• Christian O Henry,
  CFO, VP Finance
• Paul C Grint,
  Director
• Christian Cabou,
  Sr. VP and General Counsel
• Jack Goldstein,
  Director
• Joel Mc Comb,
  Sr. VP and GM, Life Sciences
• Stephen P Macmillan,
  Director
• Alan Kersey,
  V.P. & Site Manager
• John R Stuelpnagel,
  VP Business Development
• John West,
  Sr VP & GM DNA Sequencing
• David C Douglas,
  Vice President Manufacturing
• Scott D Kahn,
  Chief Information Officer
• Paulette D Cabral,
  Vice President Human Resources
• Timothy M Kish,
  VP Finance & CFO
• Arnold R Oliphant,
  VP Scientific Operations
• R Scott Greer,
  Director
• Arthur Holden,
  Sr. VP Corp and Market Dev
• David L Barker,
  Chief Scientific Officer
• Ventures Iii Lp Cw,
  10% owner
• Clinton Bybee,
  10% owner
• Keith Crandell,
  10% owner
• Kirk Malloy,
  V.P. of Customer Solutions
• George Poste,
  Director
• Robert Nelsen,
  Director
• Noemi C Espinosa,
  VP Intellectual Property
• Robert C Kain,
  Vice President Engineering
• Steven Lazarus,
  10% owner
• Venture Fund Iii L P Arch,
  10% owner
• Venture Partners Llc Arch,
  10% owner
• Christensen Jakob Wedel,
  SVP, Strategy/Corp Development
• Ankur Dhingra,
  SVP, Chief Financial Officer
• Anna Richo,
  Director
• Jose Torres,
  VP, Chief Accounting Officer
• Kevin Carl Pegels,
  Chief of Global Operations
• Scott B. Ullem,
  Director
• Carissa Rollins,
  SVP, Chief Information Officer
• John Edward Frank,
  Chief Public Affairs Officer
• Steven Barnard,
  SVP, Chief Technology Officer
• Scott D Ericksen,
  VP, Chief Accounting Officer
• Everett Cunningham,
  SVP, Chief Commercial Officer